REN and coronary artery disorder: Second, studies evaluating the impact of common genetic variation on ventricular structure and function113, 114, 117 suggest that variation in specific signaling pathways such as the renin‐angiotensin‐aldosterone system or adrenergic signaling may be suitable for pharmacologic targeting to help improve ventricular function, ventricular remodeling, and even survival in all CHD patients or in selected patients with genetic predisposition to over‐ or underactivation of those pathways.